Assessment and comparison of the 2023 ACR/EULAR APS criteria with the revised Sapporo criteria
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.15175 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von İbrahim Vasi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Predictive Value of Tests, Antibodies, Antiphospholipid, Registries. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Objective
To analyze antiphospholipid antibody (aPL)‐positive patients using the 2023 American College of Rheumatology/The European Alliance of Associations for Rheumatology (ACR/EULAR) antiphospholipid syndrome (APS) classification criteria and compare the revised Sapporo criteria and the 2023 ACR/EULAR criteria and evaluate whether the 2023 ACR/EULAR criteria provide added value over the revised Sapporo criteria.
Methods
In this descriptive study, 94 aPL‐positive patients (with or without APS diagnosis) were identified from two hospital‐based registries (Gazi and Hacettepe University). Patients were classified into four groups to compare both criteria sets. These four groups are as follows: (1) patients classified with only the revised Sapporo criteria; (2) patients classified with only the 2023 ACR/EULAR APS criteria; (3) patients classified with both two criteria sets; and (4) patients classified with neither two criteria set.
Results
Of the 94 patients, 11 were classified with only the revised Sapporo criteria; one with only the 2023 ACR/EULAR APS criteria; 52 with both criteria sets; and 30 with neither set of criteria. For these 94 patients, the operating characteristics of the 2023 ACR/EULAR APS criteria, using the revised Sapporo criteria as the gold standard, the 2023 ACR/EULAR APS entry criteria demonstrated 100% sensitivity, and the 2023 ACR/EULAR APS classification criteria demonstrated 98% specificity and 82.5% sensitivity.
Conclusion
The study emphasizes the importance of recognizing differences in clinical manifestations, such as early pregnancy loss without severe preeclampsia (PEC) and/or severe placental insufficiency (PI) and calls for a nuanced discussion on anticardiolipin (aCL) and anti‐beta 2‐glycoprotein‐I (anti‐β2GPI) immunoglobulin G (IgG) cutoff values.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
ORCID-Profile: İbrahim Vasi, Rıza Can Kardaş, Derya Yıldırım, Hazan Karadeniz, Abdurrahman Tufan, Abdulsamet Erden
Zitieren
APA
Vasi, İ., Kardaş, R. C., Ekici, M., Yıldırım, D., Kaya, B., Duran, R., Karadeniz, H., Güler, A. A., Küçük, H., Göker, B., Bilgen, Ş. A., Tufan, A., Öztürk, M. A., & Erden, A. (2024). Assessment and comparison of the 2023 ACR/EULAR APS criteria with the revised Sapporo criteria. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15175
Vancouver
Vasi İ, Kardaş RC, Ekici M, Yıldırım D, Kaya B, Duran R, et al. Assessment and comparison of the 2023 ACR/EULAR APS criteria with the revised Sapporo criteria. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15175
BibTeX
@article{Vasi2024,
author = {Vasi, İbrahim and Kardaş, Rıza Can and Ekici, Mustafa and Yıldırım, Derya and Kaya, Burcugül and Duran, Rahime and Karadeniz, Hazan and Güler, Aslıhan Avanoğlu and Küçük, Hamit and Göker, Berna and Bilgen, Şule Apraş and Tufan, Abdurrahman and Öztürk, Mehmet Akif and Erden, Abdulsamet},
title = {Assessment and comparison of the 2023 ACR/EULAR APS criteria with the revised Sapporo criteria},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.15175}
}
EUVIMED